Core Viewpoint - The recent passing of 崔福斋, a key figure in 奥精医疗, is noted, but the company asserts that this will not affect its management stability or operational independence. However, the company is facing significant challenges due to a nationwide centralized procurement policy impacting its financial performance [6][9]. Company Overview - 奥精医疗, founded in 2004 by 崔福斋, is a leading enterprise in the field of artificial bone repair materials, focusing on the research, development, production, and sales of medical devices for tissue regeneration [8]. - The company achieved a market share of 13% in the artificial bone repair materials sector in 2020 [10]. Financial Performance - In 2024, 奥精医疗 is projected to experience a revenue decline of 9.03% and a net profit decrease of 123.35%, resulting in a loss of 12.66 million yuan [6][10]. - The primary reason for this decline is the implementation of centralized procurement for orthopedic artificial bones, which has led to a significant drop in product prices and increased operational costs [10][11]. Market Dynamics - The orthopedic bone repair materials market is currently dominated by allogeneic bone, which accounts for approximately two-thirds of the market. However, legal and ethical issues surrounding allogeneic bone may enhance the market share of artificial bone repair materials [10]. - The average price reduction for orthopedic medical consumables due to centralized procurement is reported to be 74%, which has adversely affected 奥精医疗's pricing and revenue [10]. Future Outlook - 奥精医疗 is expanding its business by acquiring HumanTech Dental in 2024, which will enhance its presence in the dental implant sector [11]. - The company is also increasing its sales personnel and marketing activities, which will lead to higher sales expenses and credit impairment losses [11].

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 2025年4月26日， 奥精医疗 发布了2024年年报以及2025年一季报。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | --- | --- | --- | --- | --- | | | | | 期增减(%) | | | 营业收入 | 206,033,014.77 | 226,475,894.98 | -9.03 | 245,305,139.72 | | 扣除与主营业务无关的业务收 入和不具备商业实质的收入后 | 200,430,853.46 | 218,427,930.77 | -8.24 | 240,282,309.74 | | 的营业收入 | | | | | | 归属于上市公司股东的净利润 | -12,662,162.69 | 54,231,840.71 | -123.35 | 95,217,271.83 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | -28,371,119.81 | 25,766,199.74 | -210.11 | 80,059, ...